According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below:
GNC Holdings' interim CEO bought 592,259 shares
GNC Holdings Inc. (GNC, Financial) interim CEO Robert F. Moran bought 592,259 shares for $8.44 per share on Feb. 21. The stock price has increased by 2.25% since.
GNC is a specialty retailer of health, wellness and performance products including vitamins, minerals and herbal supplement products, sports nutrition products and diet products. The company has a market cap of $590.29 million. its shares traded at $8.63 with a price-earnings (P/E) ratio of -2.09Â as of Feb. 24.
For the fourth quarter of 2016, the company reported a net loss of $433.4 million. Consolidated revenue for the quarter was $569.9 million compared with consolidated revenue of $629.1 million for the fourth quarter of 2015.
Director Michael F. Hines bought 125,000 shares for $8.18 per share on Feb. 21. The stock price has increased by 5.5% since.
American Assets Trust CEO bought 14,653 shares
American Assets Trust Inc. (AAT, Financial) Chairman, CEO, President and 10% owner Ernest S. Rady bought 14,653 shares during the past week.
Rady bought 4,246 shares for $43.86 per share on Feb. 22. Rady also purchased 10,407 shares for $43.92 per share on Feb. 24. The stock price has increased by 0.48% since.
American Assets is a full service, vertically integrated and self-administered real estate investment trust. The company owns, operates, acquires and develops retail, office, multifamily and mixed-use properties. The company has a market cap of $2.8 billion. Its shares traded at $44.13 with a P/E ratio of 61.38Â as of Feb. 24.
Net income attributable to common stockholders was $8.9 million for the three months ended Dec. 31, 2016, compared to $8.2 million for the three months ended Dec. 31, 2015.
CNA Financial CEO bought 12,000 shares
CNA Financial Corp. (CNA, Financial) Chairman and CEO Dino Robusto bought 12,000 shares for $41.84 per share on Feb. 21. The stock price has increased by 2.58% since.
CNA is an insurance holding company. It offers commercial, property and casualty coverage, risk management, information services, warranty and claims administration. The company has a market cap of $11.61 billion. Its shares traded at $42.92 with a P/E ratio of 13.54 as of Feb. 24.
Net income for the fourth quarter of 2016 was $241 million.
Executive Vice President and Chief Financial Officer D. Craig Mense sold 318 shares for $42.42 per share on Feb. 7. Mense also sold 7,371 shares for $43.15 on Feb. 13. The stock price has decreased by 0.53% since.
Former Executive Vice President and Chief Administration Officer Thomas Pontarelli sold 236 shares for $42.58 per share on Feb. 7. The stock price has increased by 0.8% since.
Executive Vice President, General Counsel and Secretary Jonathan D. Kantor sold 382 shares for $42.65 per share on Feb. 7. The stock price has increased by 0.63% since.
PJT Partners CEO bought 8,500 shares
PJT Partners Inc. (PJT, Financial) Chairman and CEO Paul J. Taubman bought 8,500 shares for $36.73 per share on Feb. 23. The stock price has increased by 2.48% since.
PJT is an independent financial advisory firm. It provides strategic advisory, restructuring and reorganization, and funds advisory services to corporations, financial sponsors, institutional investors and governments. The company has a market cap of $1.28 billion. Its shares traded at $37.64 with a P/E ratio of -226.75.
Total revenues for the three months ended Dec. 31, 2016 were $173.5 million compared with $103.8 million for the three months ended Dec. 31, 2015.
OPKO Health CEO bought 9,000 shares
OPKO Health Inc. (OPK, Financial) CEO, Chairman and 10% owner Phillip Frost bought 9,000 shares during the past week.
Frost bought 1,800 shares for $8.8 per share on Feb. 17; 3,600 shares for $8.8 per share on Feb.21; 1,800 shares for $8.54 per share on Feb. 22; and 1,800 shares for $8.39 per share on Feb. 23. The stock price has increased by 0.6% since.
OPKO is a biopharmaceutical and diagnostics company. It is engaged in the research and development of pharmaceutical products and vaccines. The company has a market cap of $4.71 billion. Its shares traded at $8.44 with a P/E ratio of -468.89 as of Feb. 24.
Consolidated revenues for the three months ended Sept. 30, 2016 increased to $298.0 million from $143.0 million for the comparable period in 2015. Net loss for the quarter was $15.0 million compared with net income of $128.2 million for the 2015 period.
Executive Vice President-Administration Steven D. Rubin bought 2,000 shares for $8.11 per share on Feb. 8. The stock price has increased by 4.07% since.
For the complete list of stocks that were bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Start a free seven-day trial of Premium Membership to GuruFocus.
